• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The risk of COVID-19 in patients with psoriasis: A retrospective cohort study.

作者信息

Wu Jashin J, Liu Jeffrey, Thatiparthi Akshitha, Martin Amylee, Egeberg Alexander

机构信息

University of Miami Miller School of Medicine, Miami, Florida.

Keck School of Medicine, University of Southern California, Los Angeles, California.

出版信息

J Am Acad Dermatol. 2022 Dec;87(6):1395-1398. doi: 10.1016/j.jaad.2022.07.040. Epub 2022 Sep 20.

DOI:10.1016/j.jaad.2022.07.040
PMID:36305697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9484859/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/9484859/38e894d2a94c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/9484859/38e894d2a94c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/9484859/38e894d2a94c/gr1_lrg.jpg

相似文献

1
The risk of COVID-19 in patients with psoriasis: A retrospective cohort study.银屑病患者感染新型冠状病毒肺炎的风险：一项回顾性队列研究。
J Am Acad Dermatol. 2022 Dec;87(6):1395-1398. doi: 10.1016/j.jaad.2022.07.040. Epub 2022 Sep 20.
2
Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.使用阿普斯特治疗的银屑病患者中新冠病毒疾病的发病率和预后：一项多中心回顾性队列研究
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e94-e95. doi: 10.1111/jdv.17749. Epub 2021 Oct 28.
3
Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.在加拿大两家学术医院诊所和一家社区诊所的COVID-19大流行期间，患者驱动的阿普斯特停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):418-419. doi: 10.1177/1203475420928382. Epub 2020 May 12.
4
Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis.阿普司特对65例银屑病和/或银屑病关节炎患者的有效性及药物留存率
Actas Dermosifiliogr. 2022 May;113(5):532-535. doi: 10.1016/j.ad.2020.08.034. Epub 2021 Dec 17.
5
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.银屑病患者的机会性病毒感染：在新冠疫情时代阿普米拉斯更安全的选择。
Dermatol Ther. 2020 Jul;33(4):e13618. doi: 10.1111/dth.13618. Epub 2020 Jun 4.
6
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.初治生物制剂的银屑病患者开始使用阿普米司特或生物制剂的真实世界治疗模式及医疗费用
J Med Econ. 2019 Apr;22(4):365-371. doi: 10.1080/13696998.2019.1571500. Epub 2019 Feb 4.
7
Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.魁北克地区使用阿普司特治疗中重度斑块状银屑病的真实世界经验：基于药物利用和医疗资源利用的分析。
J Cutan Med Surg. 2020 Nov/Dec;24(6):573-587. doi: 10.1177/1203475420936652. Epub 2020 Jun 29.
8
Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review.有恶性肿瘤病史的患者使用生物制剂和阿普斯特治疗银屑病：一项回顾性病历审查。
J Drugs Dermatol. 2019 Apr 1;18(4).
9
Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.阿普米司特联合生物制剂治疗生物制剂治疗应答不佳的银屑病患者。
J Dermatol. 2020 Mar;47(3):290-294. doi: 10.1111/1346-8138.15193. Epub 2019 Dec 22.
10
Apremilast for a psoriasis patient with HIV and hepatitis C.阿普斯特用于一名合并感染艾滋病毒和丙型肝炎的银屑病患者。
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):e481-e482. doi: 10.1111/jdv.14301. Epub 2017 May 15.

引用本文的文献

1
COVID-19 susceptibility, severity, and vaccine effectiveness in patients with psoriasis: a nationwide cohort study in South Korea.银屑病患者的新型冠状病毒肺炎易感性、严重程度及疫苗有效性：韩国一项全国性队列研究
Sci Rep. 2025 Jul 15;15(1):25608. doi: 10.1038/s41598-025-06495-8.
2
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy.2019冠状病毒病及疫苗接种对皮肤科免疫介导炎症性疾病（特应性皮炎、银屑病和白癜风）的影响：一项Target2B!子研究
J Dermatol. 2025 Apr;52(4):624-633. doi: 10.1111/1346-8138.17664. Epub 2025 Feb 14.
3
Clinical characteristics and outcomes of psoriasis patients with COVID-19: A retrospective, multicenter cohort study in China.
中国一项回顾性、多中心队列研究：COVID-19 患者的银屑病临床特征和结局。
Chin Med J (Engl). 2024 Jul 20;137(14):1736-1743. doi: 10.1097/CM9.0000000000003024. Epub 2024 May 6.
4
Management of Psoriasis Patients with Serious Infectious Diseases.严重感染性疾病银屑病患者的管理。
Adv Ther. 2024 Jun;41(6):2099-2111. doi: 10.1007/s12325-024-02873-2. Epub 2024 May 6.
5
Decreased risk of COVID-19 and long COVID in patients with psoriasis receiving IL-23 inhibitor: A cross-sectional cohort study from China.接受白细胞介素-23抑制剂治疗的银屑病患者感染新冠病毒及出现新冠长期症状的风险降低：一项来自中国的横断面队列研究。
Heliyon. 2024 Jan 9;10(2):e24096. doi: 10.1016/j.heliyon.2024.e24096. eCollection 2024 Jan 30.
6
A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.一项关于探究2019冠状病毒病（COVID-19）与银屑病相互影响的系统评价和荟萃分析：聚焦银屑病患者的COVID-19病程及在此背景下对生物制剂的看法。
Immun Inflamm Dis. 2023 Nov;11(11):e1063. doi: 10.1002/iid3.1063.
7
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
8
Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.斑秃相关的共病：一项系统评价和荟萃分析
Am J Clin Dermatol. 2023 Nov;24(6):875-893. doi: 10.1007/s40257-023-00805-4. Epub 2023 Jul 18.
9
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.阿普米司特治疗银屑病、银屑病关节炎和白塞病的 15 项随机、安慰剂对照研究的 5 年长期安全性汇总分析。
Am J Clin Dermatol. 2023 Sep;24(5):809-820. doi: 10.1007/s40257-023-00783-7. Epub 2023 Jun 14.
10
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.